SPY343.38+1.37 0.40%
DIA282.95+0.92 0.33%
IXIC11,516.49+37.51 0.33%

Itamar Medical Sees Prelim. Q3 Sales $10.7M-$11M vs $9.57M Est.; Reinstates FY20 Sales Guidance Of $39.5M-$40.5M vs $38.38M Est.

Q3 Total Revenue Results of $10.7M to $11.0M, reflecting growth of 32%-36% Q3 U.S. WatchPAT Revenue Results of $8.6M to $8.9M, reflecting growth of 51%-56% Full Year 2020 Revenue Guidance of $39.5M to $40.5M

· 10/13/2020 06:07

Q3 Total Revenue Results of $10.7M to $11.0M, reflecting growth of 32%-36%

Q3 U.S. WatchPAT Revenue Results of $8.6M to $8.9M, reflecting growth of 51%-56%

Full Year 2020 Revenue Guidance of $39.5M to $40.5M

CAESAREA, Israel, Oct. 13, 2020 (GLOBE NEWSWIRE) --  Itamar Medical Ltd. (NASDAQ:ITMR) (TASE: ITMR), a leading medical device and digital health company focused on the diagnosis of sleep apnea and other respiratory sleep disorders, today reported preliminary unaudited revenue results for the third quarter 2020 and announced revenue guidance for the full year 2020.
        
Preliminary Third Quarter 2020 Revenue

  • Total revenue for the third quarter of 2020 is expected to be $10.7 million to $11.0 million, an increase of 32% to 36% compared to $ 8.1 million in the same quarter in 2019
  • U.S. WatchPAT revenue for the third quarter of 2020 is expected to be $8.6 million to $8.9 million, an increase of 51% to 56% compared to $5.7 million in the same quarter in 2019